The discrepancies in these studies present an apparent conflict in PRL actions in breast cancer: PRL activity has been correlated with aggressive ERα+ tumors, yet activation of the canonical PRL signaling mediator correlates with favorable outcomes. This evidence concerns the gene ESR1 and breast cancer.